DUBLIN, Oct. 12, 2021 /PRNewswire/ -- The "Cell Therapy Consumables Market by Type of Consumable, Type of Cell Therapy, Scale of Operation, Type of End-User and Key Geographical Regions: Industry Trends and Global Forecasts, 2021 - 2031" report has been added to ResearchAndMarkets.com's offering.

This report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market.

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents.

Presently, over 60 service providers are actively engaged in providing consumable/raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and/or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.

Amongst other elements, the report features:

Key Questions Answered

Key Topics Covered:

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Cell Therapy Kit Providers: List of Players 4.3. Cell Therapy Media Providers: List of Players 4.4. Cell Therapy Reagent Providers: List of Players 4.5. Analysis by Type of Consumable, Type of Cell Therapy and Application Area (Grid Representation)

5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Key Assumptions and Parameters 5.3. Methodology 5.4. Company Competitiveness: Kit Providers 5.5. Company Competitiveness: Media Providers 5.6. Company Competitiveness: Reagent Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS 6.1. Chapter Overview 6.2. Scope and Methodology 6.3. Bio-Techne 6.4. Miltenyi Biotec 6.5. Sartorius 6.6. STEMCELL Technologies 6.7. Thermo Fisher Scientific

7. COMPANY PROFILES 7.1. Chapter Overview 7.2. Miltenyi Biotec 7.2.1. Company Overview 7.2.2. Product Portfolio 7.2.3. Recent Developments and Future Outlook 7.3. STEMCELL Technologies 7.3.1. Company Overview 7.3.2. Product Portfolio 7.3.3. Recent Developments and Future Outlook 7.4. Bio-Techne 7.4.1. Company Overview 7.4.2. Product Portfolio 7.4.3. Recent Developments and Future Outlook 7.5. Irvine Scientific 7.5.1. Company Overview 7.5.2. Product Portfolio 7.5.3. Recent Developments and Future Outlook 7.6. Thermo Fisher Scientific 7.6.1. Company Overview 7.6.2. Product Portfolio 7.6.3. Recent Developments and Future Outlook 7.7. Sartorius 7.7.1. Company Overview 7.7.2. Product Portfolio 7.7.3. Recent Developments and Future Outlook 7.8. BD Biosciences 7.8.1. Company Overview 7.8.2. Product Portfolio 7.8.3. Recent Developments and Future Outlook 7.9. Lonza 7.9.1. Company Overview 7.9.2. Product Portfolio 7.9.3. Recent Developments and Future Outlook 7.10. CellGenix 7.10.1. Company Overview 7.10.2. Product Portfolio 7.10.3. Recent Developments and Future Outlook 7.11. Corning 7.11.1. Company Overview 7.11.2. Product Portfolio 7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES 8.1. Chapter Overview 8.2. Partnership Models 8.3. Cell Therapy Consumables: Recent Partnerships and Collaborations 8.4. Cell Therapy Consumables: Recent Expansions

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS 9.1. Chapter Overview 9.2. Scoring Criteria and Key Assumptions 9.3. Scope and Methodology 9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers 9.3.1. Likely Partner Opportunities for Dendritic Cell Therapy Consumable Providers 9.3.2. Likely Partner Opportunities for NK Cell Therapy Consumable Providers 9.3.3. Likely Partner Opportunities for Stem Cell Therapy Consumable Providers 9.3.4. Likely Partner Opportunities for T-Cell Therapy Consumable Providers

10. DEMAND ANALYSIS 10.1. Chapter Overview 10.2. Scope and Methodology 10.3. Global Demand for Cell Therapy Consumables 10.4. Global Demand for Cell Therapy Consumables for Planar Processes 10.5. Global Demand for Cell Therapy Consumables for Suspension Processes 10.6. Analysis by Scale of Operation 10.7. Analysis by Region

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS 11.1. Chapter Overview 11.2. Forecast Methodology 11.3. Global Outsourced Cell Therapy Consumables Market, 2021-2031 11.4. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Consumable 11.5. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Cell Therapy 11.6. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Scale of Operation 11.7. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of End-User 11.8. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Geography

12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES 12.1. Chapter Overview 12.2. Emerging Trends Related to Cell Culture Media 12.3. Automation of Cell Therapy Manufacturing Processes 12.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET 13.1. Chapter Overview 13.2. Impact of COVID-19 Pandemic on Cell Therapy Consumables Market 13.3. Impact on Future Market Opportunities for Cell Therapy Consumable Providers 13.4. Current Opinions and Key Initiatives of Key Players 13.5. Recuperative Strategies for Developer Businesses 13.5.1. Strategies for Implementation in the Short / Mid Term 13.5.2. Strategies for Implementation in the Long Term

14. CONCLUDING REMARKS 14.1. Chapter Overview

15. INTERVIEW TRANSCRIPTS 15.1. Chapter Overview 15.2. Anant Kamath, Chief Operating Officer, Cellular Engineering Technologies 15.2.1. Cellular Engineering Technologies: Key Highlights 15.2.2. Interview Transcript 15.3. Vishal G. Warke, Director R&D;, Cell Culture and Immunology, HiMedia Laboratories and Gauri W. Page, Assistant R&D; Manager, Animal Cell Culture, Himedia Laboratories 15.3.1. HiMedia Laboratories: Key Highlights 15.3.2. Interview Transcript

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

For more information about this report visit https://www.researchandmarkets.com/r/2t5jj1

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read more here:
Worldwide Cell Therapy Consumables Industry to 2031 - Featuring Bio-Techne, Irvine Scientific and Sartorius Among Others - PRNewswire